Wilson R R, Wallace A G
Angiology. 1983 Jun;34(6):367-74. doi: 10.1177/000331978303400601.
Since its approval by the FDA six years ago, oral disopyramide has earned a recognized role in the treatment of ventricular arrhythmias. During this time, clinical experience has refined our knowledge of this agent, allowing revision of dosing guidelines and better selection of patients. This review explores the recent therapeutic experience with disopyramide.
自六年前获得美国食品药品监督管理局（FDA）批准以来，口服丙吡胺在室性心律失常的治疗中已赢得了公认的地位。在此期间，临床经验完善了我们对该药物的认识，从而可以修订给药指南并更好地选择患者。本文综述探讨了丙吡胺近期的治疗经验。
